Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig plus chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma
CTR20252717Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Started Jul 2025; status: active.
02
Drugs
volrustomig
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20252717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252717.